Hip fracture prevention. Drug therapies and lifestyle modifications that can reduce risk.
The annual number of hip fractures sustained worldwide is expected to increase dramatically as the population ages. Adequate calcium and vitamin D intake and exercise are fundamental to any program for bone loss prevention or osteoporosis treatment. Fall prevention programs, weight-bearing and resistance exercise, hip protector use, and calcium and vitamin D supplementation can reduce hip fracture risk. Among the available antiosteoporosis agents, the bisphosphonates risedronate and alendronate have produced the greatest reductions in hip fracture risk in postmenopausal women. Nasal calcitonin and raloxifene have not demonstrated significant reductions in nonvertebral or hip fracture risk. The role of parathyroid hormone (1-34) in the treatment of hip fractures remains uncertain until more experience is gained about its use and studies with sufficient statistical power are performed. Data indicate that bisphosphonates consistently reduce hip fracture risk in patients with osteoporosis, especially those with an existing vertebral fracture. In addition to pharmacologic intervention, adequate nonpharmacologic preventive strategies should be included to ensure maximal reduction in risk of hip fracture.
D002116:Calcitonin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006620:Hip Fractures / Q000517:prevention & control*; D006801:Humans; D008019:Life Style; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D040242:Risk Reduction Behavior; D014807:Vitamin D / Q000627:therapeutic use
D009943:Organophosphorus Compounds; D010281:Parathyroid Hormone; D014807:Vitamin D; D002116:Calcitonin